Vera Therapeutics, Inc. - Class A (VERA)
VERA moved a median of -0.22% 30 minutes after news, and +0.07% by the close. How VERA actually reacts to news — the realized, point-in-time move the market made, measured across 343 labeled events over the last three years with zero look-ahead.
VERA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.04% | 55% | 342 |
| 30-min | -0.22% | 48% | 343 |
| 60-min | +0.08% | 52% | 343 |
| to close | +0.07% | 52% | 342 |
| Middle 50% of VERA reactions | -1.36% to +1.26% |
|---|---|
| Median reaction (30-min) | -0.22% |
| Measured reactions | 343 |
Half of all Vera Therapeutics, Inc. - Class A news events land between -1.36% and +1.26% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How VERA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | +0.61% | 60% | +1.52% |
| Coverage initiations | 27 | -1.72% | 19% | -0.28% |
| Rating reiterations | 74 | +0.03% | 51% | +0.16% |
| Price-target raises | 21 | -0.07% | 48% | +0.37% |
| Price-target cuts | 10 | +0.58% | 80% | +1.22% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how VERA ranks against every other measured name →
That’s how VERA usually reacts — get an email when it moves on news →Email me when VERA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VERA's baseline. Nothing else.
Recent VERA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.90% | -2.45% | |
| Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 | Press release | GlobeNewswire | +0.06% | -2.38% | |
| Form 8-K Vera Therapeutics, Inc. For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | -2.81% | -9.00% | |
| Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy | Press release | GlobeNewswire | -2.81% | -9.00% | |
| Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.83% | -1.45% | |
| Vera Therapeutics to Participate at Upcoming Investor Conferences | Press release | GlobeNewswire | +0.92% | +1.48% | |
| Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.74% | — | |
| Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.36% | +0.58% | |
| Form 8-K Vera Therapeutics, Inc. For: Jul 09 | SEC filing · Form 8-K | SEC EDGAR | +1.49% | +2.86% | |
| Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner | Press release | GlobeNewswire | +1.49% | +2.86% | |
| Form 8-K Vera Therapeutics, Inc. For: Jul 07 | SEC filing · Form 8-K | SEC EDGAR | +1.25% | +1.67% | |
| Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy | Press release | GlobeNewswire | -1.94% | +0.33% | |
| Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.28% | -2.46% | |
| Form 8-K Vera Therapeutics, Inc. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | +3.22% | -8.03% | |
| Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Press release | GlobeNewswire | +3.22% | -8.03% | |
| Form 8-K Vera Therapeutics, Inc. For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +2.02% | -0.20% | |
| Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.39% | +0.06% | |
| Form 10-Q Vera Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.22% | +1.00% | |
| Form 8-K Vera Therapeutics, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +0.38% | -1.62% | |
| Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | +0.38% | -1.62% | |
| Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference | Press release | GlobeNewswire | +1.57% | +1.46% | |
| Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.57% | -2.65% | |
| Form ARS Vera Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.83% | +9.53% | |
| Form DEF 14A Vera Therapeutics, Inc. For: May 21 | SEC filing · Form DEF | SEC EDGAR | -0.83% | +9.53% | |
| Form DEFA14A Vera Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.83% | +9.53% | |
| Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.92% | -2.26% | |
| Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | Press release | GlobeNewswire | +1.39% | -0.55% | |
| Form 8-K Vera Therapeutics, Inc. For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | +8.44% | -0.62% | |
| Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.18% | -0.43% | |
| Vera Therapeutics Appoints Christopher Hite to Board of Directors | Press release | GlobeNewswire | -0.01% | -0.20% | |
| Form S-8 Vera Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | +2.32% | +0.07% | |
| Form 10-K Vera Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.32% | +0.07% | |
| Form 8-K Vera Therapeutics, Inc. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -0.40% | +2.69% | |
| Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results | Press release | GlobeNewswire | -0.40% | +2.69% | |
| Vera Therapeutics to Participate at Upcoming Investor Conferences | Press release | GlobeNewswire | +0.63% | +1.19% | |
| Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.94% | +0.94% | |
| Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer | Press release | GlobeNewswire | +0.54% | -3.51% | |
| Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.00% | +0.62% | |
| Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -0.44% | -1.55% | |
| Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | Press release | GlobeNewswire | -0.22% | +2.01% | |
| Form 8-K Vera Therapeutics, Inc. For: Dec 16 | SEC filing · Form 8-K | SEC EDGAR | -0.14% | -2.33% | |
| Form 8-K Vera Therapeutics, Inc. For: Dec 09 | SEC filing · Form 8-K | SEC EDGAR | +1.15% | +3.81% | |
| Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock | Press release | GlobeNewswire | -1.16% | +2.14% | |
| Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock | Press release | GlobeNewswire | +0.19% | +7.43% | |
| Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.18% | +0.33% | |
| Form 8-K Vera Therapeutics, Inc. For: Nov 25 | SEC filing · Form 8-K | SEC EDGAR | +1.68% | +1.05% | |
| Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors | Press release | GlobeNewswire | +1.68% | +1.05% | |
| Vera Therapeutics to Participate at Upcoming Investor Conferences | Press release | GlobeNewswire | -0.38% | +2.10% | |
| Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit | Press release | GlobeNewswire | +6.88% | +6.73% | |
| Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +6.88% | +6.73% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VERA section they belong to.
Where else VERA is measured.
VERA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Vera Therapeutics, Inc. - Class A's median reaction calculated?
Every labeled VERA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 343 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of VERA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VERA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.